Although AIMP3/p18 is normally associated with multi-tRNA synthetase complex via its specific interaction with methionyl-tRNA synthetase, it also works as a tumor suppressor by interacting with ATM, the upstream kinase of p53. To understand the molecular interactions of AIMP3 and the mechanisms involved, we determined the crystal structure of AIMP3 at 2.0 Å resolution and identified its potential sites of interaction with ATM. AIMP3 contains two distinct domains linked by 7 aa (K57-S63) peptide, which contains a 3 10 helix. The 56aa N-terminal domain consists of 2 helices, into which three anti parallel β-strands are inserted, and the 111 aa C-terminal domain contains a bundle of five helices (T64-Y152) followed by coiled region (P153-L169). Structural analyses revealed homologous proteins such as yeast glutamyl-tRNA synthetase, Arc1p, EF1Bγ and glutathione Stransferase and suggested two potential molecular binding sites. Moreover, mutations at the C-terminal putative binding site abolished the interaction between AIMP3 and ATM and the ability of AIMP3 to activate p53. Thus, this work identified the two potential molecular interaction sites of AIMP3 and determined the residues critical for its tumor suppressive activity through the interaction with ATM.
Introduction
Although aminoacyl-tRNA synthetases (ARSs) catalyze the ligation of specific amino acids to their cognate tRNAs, they are multi-functional proteins that are involved in the regulation of diverse signal pathways (1) . Several ARSs of higher eukaryotes form an intriguing macromolecular protein complex with three non-enzymatic factors designated AIMPs (ARSinteracting multi-functional proteins), which are also multiply involved in various biological processes. Of these factors, AIMP1/p43 is secreted as a cytokine that functions in immune response (2, 3) , angiogenesis (4) and wound healing processes (5) and also as a hormone that regulates glucose metabolism (6) . AIMP2/p38 has been shown to mediate TGF-beta signaling for c-Myc down regulation (7) . AIMP3/18 binds to the multi-ARS complex by specifically interacting with methionyl-tRNA synthetase (MRS), and is translocated to nucleus to activate p53 through the interaction with kinases such as ATM (Ataxia telangiectasis mutated) or ATR (ATM-and Rad3-related) in response to DNA damage (8) or oncogenic stress (9) . To understand the multi-functionality and regulation of the components of the multi-ARS complex, it is important to determine the three dimensional structures of the components as well as the whole complex. So far, only the three dimensional structures of the partial domains of the complex-forming ARSs such as glutamylprolyl-tRNA synthetase (EPRS) (10, 11) , and aspartyl-tRNA synthetase (DRS) (12) , and AIMP1/p43 (13, 14) have been elucidated. Here, we report the crystal structure of full length AIMP3 and the residues and location required for the interaction with ATM.
Experimental Procedures
Cloning, expression and purification of human AIMP3 -The cDNA encoding human AIMP3 was amplified by PCR and subcloned into pP RO EX Hta (NdeI), a hexahistidine (His 6 ) fusion expression vector containing a recombinant TEV protease (rTEV) cleavage site and a site for NdeI. For the SeMet-substituted protein preparation, T42, I70 and K95 residues were replaced by methionine using site-directed mutagenesis since the N-terminal methionine residue was not sufficient for phasing in structural determination. To improve crystal quality, the C-terminal five residues (Y170-H174) was truncated because it is thought to be flexible based on secondary structure prediction. The resulting recombinant vectors, pP ROEX HTa:AIMP3, pP ROEX HTa:AIMP3(ΔC5) and SeMet-substituted AIMP3 (ΔC5, T42M/I70M/K96M) were transformed into the methionine auxotroph E. coli strain B834 (Novagen).
Transformants were grown in an LB medium containing ampicillin at 37 o C until reaching an OD 600 between 0.6 and 0.8. After induction with 1.0 mM IPTG, cultures were grown for a further 20 h at 22°C. The cells were then harvested by centrifugation at 5,000 g for 20 min at 4°C. SeMet-substituted AIMP3 (ΔC5, T42M/I70M/K96M) was expressed in minimal medium (M9) supplemented with 50 mg/ml SeMet. Cell pellets were resuspended in icecold buffer A (50 mM Tris-HCl, pH 8.0, 5 mM β-mercaptoethanol) and disrupted by ultrasonication. These crude cell extracts were then centrifuged at 11,000 g for 1 h at 4°C. Cell lysates containing His 6 -tagged AIMP3 were then bound to Ni-NTA agarose (QIAGEN) equilibrated with buffer A. After washing with buffer A containing 10 mM imidazole, bound proteins were eluted with buffer A containing 300 mM imidazole. His 6 -tag was then removed from AIMP3 by incubating with rTEV protease (GIBCO), followed by Ni-NTA agarose and ion exchange chromatography with HiTrap Q Sepharose (GE Healthcare). AIMP3 proteins contain two additional residues (Gly-Ala) at the N-terminus due to the cloning procedure. Final protein yields were approximately 8-10 mg/l, as determined by the Bradford procedure (BioRad). Protein homogeneity was assessed by 10% SDS-PAGE and Coomassie Blue staining.
The purified AIMP3 was then dialyzed against 50 mM Tris-HCl, pH 8.0, containing 300 mM NaCl, concentrated to 15 mg/ml, and stored at -80°C.
Crystallization, data collection and structure determination -AIMP3 proteins were concentrated and subjected to initial crystallization screening at 293 K, using a sitting drop-vapor diffusion method with commercially available crystal-screening solution sets from Hampton Research and Emerald Biosystems. Full-length AIMP3 crystals were obtained using 0.1 M sodium cacodylate buffer (pH 6.5) containing 30% PEG 8000 and 0.2 M sodium acetate. In the case of the deletion mutant protein, after optimization, the best crystals were obtained under the condition of 15% PEG 10,000 in 0.1 M HEPES at pH 5.5. However, none of crystals diffracted well. Finally, the SeMet-substituted AIMP3 deletion mutant protein (hAIMP3ΔC5, T42M/I70M/K96M) was subjected to crystallization screening. Crystallization conditions were optimized as 4 % benzamidineHCl and 10 % PEG 10,000 in 0.1 M HEPES buffer at pH 7.0 with 2 μl of 15 mg/ml protein and 2 μl of the reservoir solution at 16 o C. Crystals appeared within 2 days and grew for about 5 days to reach maximal dimensions of approximately 0.1 x 0.1 x 0.1 mm.
A single crystal was transferred to the reservoir solution containing 20% glycerol as a cryo-protectant prior to X-ray data collection. Single-wavelength anomalous dispersion (SAD) data were collected at 0.9795 Å, the wavelength corresponding to Se absorption peak, using an ADSC Quantum 210 CCD area detector at 6C1 beamline (MXW) at Pohang Accelerator Laboratory (PAL, Pohang, Korea). The completeness of the data collected was 98.3% at a resolution of 2.5 Å. This crystal was also used for data collection at a wavelength of 1.2399 Å, which produced the highest photon flux could be obtained at beamline. Using longer exposure time, diffraction data were collected at higher resolution (2.0 Å). Data were integrated and scaled using the HKL2000 suite (15) . The crystal belonged to the C222 1 space group with unit cell parameters of 46.3 x 77.9 x 194.8 Å. Six of the Se atoms in the asymmetric unit were found using SOLVE (16) . The asymmetric unit contained two molecules and the value of the Matthew's coefficient was 2.25 Å 3 /Da, corresponding to a solvent content of 45.3%. The overall figure of merit (FOM) was 0.347. Density modification and subsequent automated model building were done using RESOLVE (17) , which increased FOM to 0.694 with 76% (259 amino acid residues) of the residues incorporated. Further model building was performed manually into density-modified electron density map using the program O (18) and Coot (19) , and refinement with isotropic displacement parameters was performed using CCP4 refmac5 (20) . In the final model, a loop region (G84 to K88) in both AIMP3 molecules was not unassigned because electron density was poor in this region. The R work and R free values of the refined structure are 0.204 and 0.245, respectively. Crystallographic data statistics are summarized in Supplementary Determination and generation of AIMP3 mutations -Bone marrow cells of chronic myeloid leukemia patients were obtained from the Korean leukemia cell and gene bank. Total RNAs were isolated from the cells of each patient using RNeasy (QIAGEN) and subjected to RT-PCR to generate the AIMP3 cDNAs. These were then subcloned to pcDNA 3.1/His topo vector (Invitrogen) and mutations were determined by DNA sequencing. Point mutations in AIMP3 were generated via sitedirected mutagenesis using Quickchange kit (Stratagene). All generated mutants were confirmed by DNA sequencing.
GST pull-down assay -AIMP3 wild-type and mutants were synthesized by in vitro translation in the presence of [ 35 S]-methionine using coupled translation kit (TNT, Promega). MRS (900 aa full-length) and (641 aa FAT domain of ATM) were expressed as GST fusion proteins. Aliquots (10 μl) of TNT products were incubated with 5 μg GST fusion proteins immobilized to glutathione-Sepharose 4B in 500 μl of PBS containing 0.5% Triton X-100, 0.5 mM EDTA, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF). The beads were incubated for 2hr at 4 o C with rotation and 3 times washed with PBS buffer. After addition of SDS sample buffer, the bound proteins were eluted by boiling, separated by SDS-PAGE, and determined by autoradiography. 
Co-immunoprecipitation -

Luciferase reporter gene assay -HCT116 p53
+/− cells were grown in RPMI medium (HyClone) supplemented with 10% fetal bovine serum and penicillin/streptomycin. Each of the plasmids encoding the wild type and mutant AIMP3 was transfected with p21-luciferase (kind gift of S. J. Um, Sejong University) and the β-galactosidase plasmids by electroporation using microporatormini (Digital Bio). Preparation of cell extracts, ß-galactosidase and luciferase assays were performed according to the manufacturer's protocol (Promega). The values are the averages of at least two separate experiments and were normalized to those of ß-galactosidase resulting from the expression of the internal control plasmid pCMVßgal.
Results
Overall structure. The three-dimensional structure of human AIMP3 was determined by X-ray crystallography using SAD, and refined to a crystallographic R factor of 0.204 at 2.0 Å resolution. The details of data collection and refinement statistics are summarized in Supplementary Table 1. Two AIMP3 molecules (A and B) were found to be present in the asymmetric crystal unit, and to be related by a non-crystallographic two-fold axis of symmetry. AIMP3 consists of seven α-helices and three β-strands and is divided into two structural domains (Fig. 1A) . The N-terminal domain (AIMP3-N) spanning residues from M1 to N56, contains two α helices (α1 and α2) and three β strands. The three-stranded antiparallel β-sheets are inserted between the two helices facing the same side of the β-sheet. The β-sheet flanked by the parallel helices α1 and α2 on one side and exposed to solvent on the other side. The linker of 7 residues (K57 to S63), in which the peptide from E58 to L61 forms 3 10 helix, connects the two domains. A short turn helix is also found in the linker connecting two domains in the structures of GSTs from maize (22) and mosquito (23) . The C-terminal domain (AIMP3-C) consists of a bundle of five helices (α3 to α7) (T64 to Y152) and a following coil region (P153 to L169). Two helices α3 and α5 of the helical domain face to the helices of N-AIMP3 forming a four-helix bundle like structure. There are hydrophobic interactions between residues L10, L14, V52, L75, I118, and L119 of the two domains that stabilize the structure with an additional ion interaction (E6 from helix α1 and R78 from helix α3). Helix α5, which runs anti parallel to helix α4 and parallel to helix α3, bends away from the AIMP3-N at its Cterminal end. Residues from G84 to K88 between helices α3 and α4 were not defined because of poor electron density in both molecules A and B, suggesting a flexible loop connecting the two helices. Average B-factors of molecules A and B are 31.7 Å 2 and 33.4 Å 2 , respectively. In both molecules, the B-factor of AIMP3-N is higher than that of AIMP3-C, which contains stable inter-helices interactions, suggesting a possible movement in the Ndomain (Fig. 1B) . Specifically, B-factors at loops connecting β-strands are high. Side chains of K18, K21, and E27 in the loops are missing in both molecules. Two AIMP3 molecules in an asymmetric unit have essentially the same conformation. RMSD of main chain atoms between two molecules is 0.651 Å. The superimposed two molecules, however, show a little difference in the relative position of AIMP3-N to AIMP3-C (Fig. 1C) , implying a potential inter-domain movement.
Structural similarity. A search using DALI program (24) yielded several proteins structurally similar to AIMP3, including GSTs and other proteins with GST-fold (Supplementary Table 2 ). E. coli GST (25) has the greatest Z-score (14.1) and other proteins including yeast elongation factor 1Bγ (EF1Bγ) (26) , prostaglandin D synthase (27) , yeast prion protein Ure2p (28) , E. coli stringent starvation A (29) , and N-terminal domains from yeast Arc1p (arc1p-N) and glutamyl-tRNA synthetase show Z-scores ranging from 9.9 to 13.9 (30) . Arc1p forms a trimeric complex with glutamyl-(ERS) and methionyl-tRNA synthetase (MRS) in yeast (31) . All proteins except Arc1p have a similar two-domain structure like GST, while Arc1p lacks a motif corresponding to the N-terminal domain of GST. The conformation of Arc1p-N is similar to AIMP3, though it does not possess the N-terminal β-sheet and α2 helix of AIMP3 ( Fig. 2A) . Arc1p has a α helix ahead of the helical domain, which corresponds to the Cterminal domain of GST, and this first helix is apart from the second helix and locates near the fourth helix like helix α1 in AIMP3-N. It also has a similar linker region containing a 3 10 helix between the first helix and the helical domain.
AIMP3-N possesses a three-stranded anti parallel β-sheet with a strand order of 1-2-3 ( Fig. 2B ) while GST and other structurally related proteins contain a four-stranded mixed β sheet in their N-terminal domains. Furthermore, GST has a β strand at its N-terminus that is inserted between β2 and β3 strands forming strand order of 2-1-3-4 ( Fig. 2C) . Although ERS has a three-stranded β-sheet, it has a long loop connecting β3 strand and α2 helix in the position corresponding to the β4 strand of GST implying a dissolved fourth β-strand (Fig. 2D) . A short β1-β2 loop makes AIMP3-N smaller than other proteins. E. coli GST contains an additional strand and α helix in β2-β3 loop corresponding to the β1-β2 loop of AIMP3 (Fig.  2C ). EF1Bγ contains an extra helix and turn in that loop (Fig. 2E ). These differences in the presence of an underlying overall similarity implicate that these proteins might have their unique functions.
Although overall folding of the Cterminal α-helical domains of AIMP3 and related proteins are similar, the length of the helices and conformation of the C-terminal tails show difference. AIMP3-C shows more similarity to C-terminal domains of ERS and Arc1p than those of GST or EF1Bγ, which have longer α3 and α4 helices. Arc1p has a shorter α4 helix and α3-α4 loop while ERS has a helical C-terminal tail. Despite that overall amino acid sequence homologies between these proteins are low (13 -23% identity), there are discernable sequence similarities in the core region of helical domain and motifs like helices α3 and α7. For example, the sequence of AIMP3 helix α7 (VNVSRWYTL) is similar to ERS helix (LNVSRWFCH) with the conserved arginine at R144 of AIMP3, R164 of ERS, R190 of EF1γ, and R100 of Arc1p.
Putative binding sites. Crystallographic inspection suggests that AIMP3 can make two types of interactions. In an asymmetric unit, two molecules A and B are arranged by a noncrystallographic two-fold axis (Fig. 3A) . Helix α7 and the loop between helices α4 and α5 are involved in the interaction. The other interaction type is a dimer formation by a crystallographic two-fold axis (Fig. 3B) . Helices α2 and α3 from both monomers are arranged to form four-helix bundle and helix α3 of one monomer binds to the interface between β3 strand and α2 helix of the other monomer. Two different topologically identical dimers, i.e., A-A and B-B, could be formed by crystallographic axis. Side chains of Q73 and E76 from helix α3 have hydrogen bonds with hydroxyl groups of T45 and T46 from helix α2 and main chain nitrogen of T42 of anther monomer. There are additional interactions between guanidine group of R28 and main chain oxygen atoms of T80 and D83.
The interaction between the two AIMP3 molecules related to the crystallographic twofold axis is similar to that shown by GST dimer in which interactions occur around helix α3 (Fig.  3C) . The GST-like domain of EF1Bγ mediates the dimerization of the EF1 complex, which in yeast is a dimer of the heterotrimer EF1A:EF1Bα:EF1Bγ. Residues from both Nterminal thioredoxin-fold and C-terminal α helical domain of EF1Bγ form the dimer interface. In the trimeric complex of yeast Arc1p with ERS and MRS (32) , the N-terminal domains of Arc1p and MRS form a complex similar to the homodimers of GST and AIMP3 (Fig. 3D) . Together with sequence homology at helix α3, the area around residues A69, E72, Q73, E76 and T80 from helix α3 is thought to constitute a putative binding site for the molecular interaction of AIMP3 (Fig. 3G, PBS-I) .
The interaction between ERS and Arc1p includes interactions along their helices α6, which correspond to the helix α7 of AIMP3 (Fig.  3E) . The stacking of R164 from ERS and R100 from Arc1p makes their key interaction and the interface of the two proteins exhibits a large number of inter-atomic interactions (32) . This interaction shows the "lock-and-key" complimentary features of a hydrophobic surface with a limited number of the electrostatic interactions. It is similar to the interaction of two AIMP3 molecules in an asymmetric unit involving a region of helix α7 and a loop between helices α4 and α5. As aforementioned, the sequence of AIMP3 helix α7 is well conserved in the corresponding helix of ERS. R144 residues from helices α7 of two AIMP3 molecules are stacked each other and have hydrogen bond network through water molecules with main chain carbonyl oxygen of E103 of the other AIMP3 (Fig. 3F) . N141 also shows water-mediated hydrogen bonds with N141 and E103 of the other molecule while V106, Y107, and H148 from both monomers are in close proximity. Based on this structural feature and sequence homology, this interaction is predicted to provide another putative binding site for AIMP3 (Fig. 3H, 
PBS-II).
Mutagenesis. We also investigated the functions of AIMP3 residues that are important for its interaction with ATM, because the binding of these two proteins is critical for the tumor suppressive activity of AIMP3. It has been reported that AIMP3 heterozygous mice developed various cancers including lymphoma at high frequency, and furthermore, the allelic deletion of AIMP3 is often observed in cancer patients including leukemia patient (8) . To identify mutations affecting the interaction of AIMP3 with ATM, we isolated the gene encoding AIMP3 from 20 different chronic myeloid leukemia (CML) patients. Fourteen of these cases contained mutations at the different residues of AIMP3 (Supplementary Table 3) , and of these mutations, E76/T80 and V106/ R144 are located at the putative binding site I and II, respectively ( Fig. 4A and B) . Moreover, S87 resides in the loop between helices α3 and α4, and T35 and S40 are in the extruding β hairpin consisting of β2 and β3 strands. The side chain of T35 faces to helix α2 while the S40 side chain is exposed to solvent (Fig. 4A and B) .
Effect of mutation on ATM binding and p53 activation.
We introduced alanine substitutions to the residues of AIMP3 (T35/S40, T76, T80, S87, V106 and R144) whose mutations have been identified in CML patients and examined whether any of these mutations affects its interactions with ATM and MRS using in vitro pull down and co-immunoprecipitation assays. ATM is a 3056 aa kinase that is involved in cell cycle control and DNA repair, and consists of FAT (TRAP/ATM/TRRAF conserved), PI3K-catalytic and C-terminal domains. Here we used the 641 aa FAT domain of ATM, which was previously shown to be involved in its interaction with AIMP3 (33), and full-length MRS. AIMP3 wild-type and mutants were prepared by in vitro translation in the presence of [ 35 S] and mixed with the FAT domain of ATM or MRS that were expressed as GST fusion proteins. GST proteins were precipitated using glutathione-Sepharose and the co-precipitation of AIMP3 mutants was followed by autoradiography. It was found that mutants at T35/S40, E76 and T80 co-precipitated with ATM like wild type AIMP3, but that S87A, V106A and R144A mutants lost their ATM binding ability (Fig. 5A) . However, all of these mutants still retained their ability to bind MRS (Fig. 5B) , suggesting that AIMP3 may associate with the two target proteins in different manners or affinity. We also checked the effect of these mutations on the cellular interaction between AIMP3 and ATM by co-immunoprecipitation. Myc-tagged AIMP3 wild-type or mutants were co-expressed with Flag-ATM in 293 cells, which were then subjected to UV irradiation. Flag-ATM was immunoprecipitated with anti-Flag antibody and co-precipitated AIMP3 mutants were determined by immunoblotting with antiMyc antibody. All of the mutants except for R144A mutant were expressed to a level comparable with that of wild type AIMP3, suggesting that these mutations did not affect the cellular stability of AIMP3 (Fig. 5C lower  panel) . However, the expression of R144A mutant was significantly lower than others after transfecting the same amount of the plasmid, which implied that this mutation had destabilized the protein structure (data not shown). In this assay, T80A, S87A, V106A and R144A mutants were not co-precipitated with ATM (Fig. 5C ). Although loss of interaction for S87, V106 and R144 mutants had already been demonstrated by the pull-down assay above, T80A mutant was newly identified to be defective in terms of ATM binding by coimmunoprecipitation. At this moment, it is not clear why T80A mutant cannot bind ATM in the cells while retaining its ATM binding ability in vitro. Perhaps, it is defective in nuclear localization, which is required for the interaction with ATM or in dissociation from MRS. Our combined findings concerning predicted putative binding sites and the effects of mutation on ATM binding, suggest that putative binding site II, which includes V106 and R144, is likely to be involved in the interaction with ATM.
We then introduced the AIMP3 wild type and mutants into HCT116 cells harboring the luciferase reporter under p21 promoter and irradiated transfectants with UV. While transfection of wild-type AIMP3 enhanced the luciferase activity about 4 fold, all mutants except for T35/S40 mutant demonstrated less luciferase activity than the wild type (Fig. 5D) . In this assay, the three mutations at S87, V106 and R144 that blocked the interaction of AIMP3 with ATM, most dramatically reduced the luciferase activity, which suggests that these residues are functionally important for p53 activation and ATM interaction.
Discussion
Multi-ARS complex harbors many multifunctional enzymes and associated factors, and is considered as molecular depot or signalosome (1, 34) . Thus, it is important to understand the molecular assembly and dynamic status of it components in order to comprehend how the multi-tasking of this complex is regulated. The complex consists of nine different ARSs and three AIMPs. Among these components, GST homology domains are found in the N-terminal appendices of two ARSs (MRS and EPRS) and two AIMP2 (AIMP2 and AIMP3) (35) . Since these domains are only detected in these complex-forming ARSs and AIMPs, and the Nterminal appendix of VRS (valyl-tRNA synthetase) that also forms a complex with elongation factor (36), they are thought to be critical for the assembly of protein complexes. In fact, we observed that the N-terminal appendix of MRS which contains a GST homology domain interacts with AIMP3 (data not shown), further supporting this notion. In this interaction pair, AIMP3 is required for the cellular stability of MRS but does not need MRS for its own stability (37) . Another target protein of AIMP3, ATM, does not contain a GST homology domain, suggesting that AIMP3 may associate with ATM in a different manner. In fact, mutations of AIMP3 that abolished the interaction with ATM did not influence its binding to MRS (Fig. 5A and B) . Although AIMP3 is necessary for the stability of MRS, it also functions as a positive regulator of the kinase activity of ATM (8) . In addition, AIMP3 could target itself to form a homodimer as implied by crystal packing shown in the present study and by previous yeast two hybrid analyses (38) . Nonetheless, gel filtration analysis of the purified AIMP3 showed no solid evidence of homodimer in solution (data not shown).
We previously found that AIMP3 is translocated into nucleus in the presence of DNA damage (8) or oncogenic stress (9) . Since its nuclear translocation occurs within 15 min of UV irradiation, it does not appear to involve de novo synthesis. Instead, AIMP3 bound to the multi-ARS complex could dissociate from the complex and subsequently translocated to the nucleus. If it is the case, the binding of AIMP3 to its two target proteins, MRS and ATM, might be controlled by post-translational modification.
In this regard, it should be noted that EPRS (glutamyl-prolyl-tRNA synthetase), the largest component of multi-ARS complex, is phosphorylated and dissociates from the complex after IFN-γ treatment to form some different type of multi-protein complex that is required for gene silencing (39) . Thus, it is possible that AIMP3 binding and movement could also be controlled by phosphorylation or some other post-translational modification.
Among the three residues which abrogated ATM binding ability, V106 and R144 are located in the putative binding site II (Fig. 4) , and thus, are expected to be involved in the interaction with ATM. However, S87 is unlikely to be directly involved in the binding to ATM since it is rather remote from the putative binding site II and faces the other side (Fig. 4) . Perhaps, S87 is involved in post-translational modification or the disposition of the binding site for the interaction with ATM. On the other hand, mutation at R144 not only abolished the ATM binding ability but also appeared to destabilize the protein folding (data not shown). For this reason, we had to transfect much larger amount of the encoding plasmid to express this mutant to the level comparable to those of the wild type or other mutants. Since the two amino groups of the R144 side chain form hydrogen bonds with the carbonyl oxygen of L102 and K105 to stabilize the interaction between helix α4 and α7 (Fig. 3F) , loss of this residue might result in the unfolding the C-terminal domain. At present, it is unclear why the mutants beyond binding site II reduced the ability of AIMP3 to activate p53 (Fig. 5D) . Perhaps, they can still bind but not efficiently activate ATM, or indirectly influence the conformation of the ATM binding site in AIMP3.
Since AIMP3 exerts its tumor suppressive activity by binding ATM, any mutation that affects their binding is likely to be etiologically associated with cancer formation. In the present study, we identified several mutations of AIMP3 isolated from clinical specimens of CML patients. CML is a neoplastic disease of haemopoietic stem cells, and is caused by the expression of abnormally fused BCR/ABL tyrosine kinase. This oncogenic kinase is encoded by the Philadelphia chromosome that results from the translocation between chromosome 9 and 22, which harbor cabl and bcr genes, respectively. Although its molecular pathogenesis is relatively well known compared to those of other cancers, additional mutations at other critical genes could be associated with disease progression or drug resistance. At present, we do not know whether these mutants have any pathological implications for CML. Nevertheless, since AIMP3 is critical for the stability of chromosome structure (9) , mutations affecting AIMP3 activity could be associated with the initiation or progression of leukemia or other related cancers. Although these questions need further investigation, the presence of the mutations found from cancer patients, which affect the interaction of AIMP3 with ATM and its ability to activate p53, further support the functional significance of AIMP3 in the control of tumorigenesis. Furthermore, the interface between AIMP3 and ATM identified from this work provides a new therapeutic window for the development of novel anti-cancer agents. shown. AIMP3 and ERS have three-stranded β-sheet whereas GST and EF1Bγ have four-stranded β-sheet. While AIMP3 contains anti parallel β-sheet, the other three proteins have a β strand at the Nterminus forming mixed β-sheet. Additional secondary structures in the long loop between β2 and β3 strands are present in GST and EF1Bγ . , and rat (XP_214451). The alignments shown represent secondary structures of human AIMP3. Conserved residues set against a red background. Mutated residues in AIMP3 identified from CML patients are marked with arrow heads. Two putative binding sites and a missing loop are marked as PBS-I, PBS-II and ML. Multiple alignment was done using the T-coffee software and visualized using ESPript (http://esprit.ibcp.fr/ESPript/ESPript/). (B) Spatial locations of AIMP3 mutations isolated from leukemia patients. Mutational residues, T35 and S40, are located in the N-terminal domain, V106, R141, and R144 in the C-terminal domain, and E76, T80, and S87 in the loop connecting β3 and β4 strands. +/-cells were transfected with p21-dependent luciferase and AIMP3 WT or the individual mutants. Cells were irradiated with UV at 50 J/m 2 and then incubated for 2 h. They were then lysed and luciferase activities were measured and normalized by the β-galactosidase activity that was cotransfected with luciferase. Experiments were performed in triplicates and repeated twice. Averaged values were shown in the bar graph. 
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